Oxaloplatino [Spanish]
Categoria
Oxaloplatino [Spanish] Marchi, Oxaloplatino [Spanish] Analoghi
Oxaloplatino [Spanish] Marchi miscela
Oxaloplatino [Spanish] Formula chimica
Oxaloplatino [Spanish] RX link
Oxaloplatino [Spanish] FDA foglio
Oxaloplatino [Spanish] DMS (foglio di materiale di sicurezza)
Oxaloplatino [Spanish] Sintesi di riferimento
Oxaloplatino [Spanish] Peso molecolare
Oxaloplatino [Spanish] Temperatura di fusione
Oxaloplatino [Spanish] H2O Solubilita
Oxaloplatino [Spanish] Stato
Oxaloplatino [Spanish] LogP
Oxaloplatino [Spanish] Forme di dosaggio
Oxaloplatino [Spanish] Indicazione
Oxaloplatino [Spanish] Farmacologia
Oxaloplatino [Spanish] Assorbimento
Oxaloplatino [Spanish] Tossicita
Oxaloplatino [Spanish] Informazioni paziente
Patients and patientsí caregivers should be informed of the expected side effects of ELOXATIN, particularly its neurologic effects, both the acute, reversible effects, and the persistent neurosensory toxicity. Patients should be informed that the acute neurosensory toxicity may be precipitated or exacerbated by exposure to cold or cold objects. Patients should be instructed to avoid cold drinks, use of ice, and should cover exposed skin prior to exposure to cold temperature or cold objects.
Patients must be adequately informed of the risk of low blood cell counts and instructed to contact their physician immediately should fever, particularly if associated with persistent diarrhea, or evidence of infection develop.
Patients should be instructed to contact their physician if persistent vomiting, diarrhea, signs of dehydration, cough or breathing difficulties occur, or signs of allergic reaction appear.
![Oxaloplatino_[Spanish]](/images/rx/APRD00186.gif)
